Royal Bank of Canadahttps://www.rbcroyalbank.com/personal.htmlhttps://www.rbcroyalbank.com/personal.htmlInsights1200630enCA
Datum[@Name='Source DCR']
2020-05-26New business models emergeWill genetics usher in a new era of healthcare? Is the entire health ecosystem ready for reinvention? Can digital healthcare in life sciences exceed patient expectations?Expanding Ecosystems3/assets/rbccm/images/gib/healthcare/article_3_thumbnail_sm.jpg/assets/rbccm/images/gib/healthcare/article_3_thumbnail.jpg<h3>Shifting Paradigms</h3>
<p>As the convergence of healthcare and technology has accelerated, new business models are rapidly emerging. </p>
<p>In the traditional biopharma model, the customer would be a physician, R&D tools would be chemical or biological, the end product a pill or vial, and the competitors pharma and biotech players.</p>
<p>The digital revolution in healthcare is shifting this long-established paradigm. Today, biopharma companies’ customer groups have grown to include patients of all ages, providers and payers—all equipped with smartphones and apps that generate a vast amount of digital information to empower their decision-making. R&D has added genetic information and digital capability to its toolset. The end product has broadened beyond the pill to include health outcomes enabled by digital devices and therapeutics. And the competitive set has seen the addition of technology players, including consumer-focused apps and online services, as well as digital health and digital therapeutics firms.</p>
<p class="photo-frame text-center"><img style="width: 100%;" src="/assets/rbccm/images/gib/healthcare/Healthcare-Article-3-Graph-1.png" alt="" /></p>
<h3>A Changing Ecosystem</h3>
<p>Indeed, digital and AI applications are radically changing key areas of the biopharma ecosystem and how patients manage their healthcare.</p>
<p>In pre-clinical research, technology is enabling everything from a deeper mining of literature, to predictive modeling and gene-function annotation. Digital apps are simulating molecular dynamics and pushing the limits of cellular imaging.</p>
<p>In clinical trials, digital transformation is helping to automate testing procedures, build global patient databases and collect real-world data.</p>
<p>In diagnostics, tech powers digital pathology, home-based body diagnosis, and computational analysis of tissue arrays. Just like your car leaves the factory with hundreds of sensors that can trigger the check engine light, humans will have wearable and/or implantable sensors to alert them when something is not functioning properly. Another burgeoning area is immune cell monitoring and digital analysis through just a finger prick.</p>
<p>At the point of patient care, digital applications are already delivering virtual consultations, remote monitoring, VR-based cognitive therapy and digital Rx. Demand for telehealth services and health-based social platforms is also increasing and especially vital in a world facing new challenges such as the COVID-19 pandemic.</p>
<p><img src="/assets/rbccm/images/gib/healthcare/healthcare-article-3-graph-2.png" alt="AI and Digital applications are changing key areas of the Healthcare Ecosystem" /></p>
<div id="similar-to-this" style="border-top: 2px #E6E6E7 dotted; border-bottom: 2px #E6E6E7 dotted; margin: 35px 0; padding: 25px;">
<h4 style="font-size: 18px; letter-spacing: 0.5px; border-bottom: 3px #FEDF01 solid; padding: 0 0 8px 0; margin-bottom: 15px;">Similar to this</h4>
</div>
<h3>Digital Transformation</h3>
<p>The digital revolution presents both threats and opportunities to incumbent biopharma companies. Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities from treatment to prevention.</p>
<div class="quotebox">
<p>“Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities.”</p>
<p class="attribution" style="color: #0070a3;">– Greg Wiederrecht, Ph.D.</p>
<div class="quote-share">
<p style="display: inline-block;"><span style="margin-right: 15px;">Share </span><a class="blue-circle-outline-sm" href="https://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New%20healthcare%20business%20models%20emerge&source=www.rbccm.com" target="_blank" rel="noopener" aria-label="Connect by LinkedIn"><em class="fa fa-linkedin" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="https://twitter.com/home?status=New%20business%20models%20emerge%20https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge" target="_blank" rel="noopener" aria-label="Connect by X"><em class="fa fa-twitter" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="mailto:?subject=New%20business%20models%20emerge&body=I%20found%20this%20insights%20piece%20from%20RBC%20Capital%20Markets%20informative%20and%20thought%20it%20might%20be%20of%20interest%20to%20you%3A%0D%0Dhttps%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New business models emerge" aria-label="Connect by Email"><em class="fa fa-envelope" style="color: #0051a5; margin-left: 3px;"> </em></a></p>
</div>
</div>
<p> </p>
<p>The increased digitization of human experiences gives access to a wealth of information and knowledge that could help intervene before disease has a chance to strike. A prime example of this is collating data from an Apple Watch to screen for irregular heart rhythms and detect undiagnosed atrial fibrillation. At the other end of the spectrum, digital transformation allows a completely new class of therapies such as digital therapeutics to support specific disorders.</p>
<p>McKinsey and Company’s international survey shows that more than 75% of patients expect to use digital healthcare services in the future.<sup>1</sup> Patients are seeking technology that delivers a level of care they can rely on and trust. Ultimately, the aim of the digital revolution is to develop healthier societies and lower the cost of care.</p>
<p style="word-wrap: break-word;"><sup>1 Source: McKinsey and Company, Healthcare’s Digital Future, July 2014. https://www.mckinsey.com/~/media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/Healthcares%20digital%20future/Healthcares%20digital%20future.ashx</sup></p><ul>
<li>Customer groups, R&D and competitors are all rapidly expanding</li>
<li>Tech is reinventing every facet of the biopharma ecosystem</li>
<li>Innovations in patient care is driving adoption of digital services</li>
</ul>text2 min1 minHealthcare Models, Digital Healthcare, Digital Healthcare Apps, Digital Health Diagnostics, Expanding R&D, Healthcare & Tech Convergence, Healthcare Services, Clinical Trials, Remote Patient Monitoring, Digital Therapeutics, Biopharma ecosystem, Cost of CareN/templatedata/rbccm/episode/data/healthcare/amazon_cvs_and_google_healthcare_reimagined/templatedata/rbccm/episode/data/healthcare/big_tech_vs_big_pharma/templatedata/rbccm/episode/data/healthcare/the_healthcare_data_explosionGreg Wiederrecht, Ph.D./assets/rbccm/images/gib/healthcare/greg-wiederrecht.jpgManaging Director, Healthcare Investment Bankinggreg.wiederrecht@rbccm.comhttps://www.linkedin.com/in/gregwiederrecht/Sasson Darwish/assets/rbccm/images/gib/healthcare/sasson-darwish.jpgManaging Director, AI, Analytics and IoT & Israel Country Coverage, Global Technology Investment Bankingsasson.darwish@rbccm.com https://www.linkedin.com/in/sassdarwish/Andrew Callaway/assets/rbccm/images/gib/healthcare/andrew-callaway.jpgManaging Director, Global Head of Healthcare Investment Bankingandrew.callaway@rbccm.comhttps://www.linkedin.com/in/andrew-cal-callaway
DEBUG: DCR
DCR
Royal Bank of Canadahttps://www.rbcroyalbank.com/personal.htmlhttps://www.rbcroyalbank.com/personal.htmlInsights1200630enCA
DCR
2020-05-26New business models emergeWill genetics usher in a new era of healthcare? Is the entire health ecosystem ready for reinvention? Can digital healthcare in life sciences exceed patient expectations?Expanding Ecosystems3/assets/rbccm/images/gib/healthcare/article_3_thumbnail_sm.jpg/assets/rbccm/images/gib/healthcare/article_3_thumbnail.jpg<h3>Shifting Paradigms</h3>
<p>As the convergence of healthcare and technology has accelerated, new business models are rapidly emerging. </p>
<p>In the traditional biopharma model, the customer would be a physician, R&D tools would be chemical or biological, the end product a pill or vial, and the competitors pharma and biotech players.</p>
<p>The digital revolution in healthcare is shifting this long-established paradigm. Today, biopharma companies’ customer groups have grown to include patients of all ages, providers and payers—all equipped with smartphones and apps that generate a vast amount of digital information to empower their decision-making. R&D has added genetic information and digital capability to its toolset. The end product has broadened beyond the pill to include health outcomes enabled by digital devices and therapeutics. And the competitive set has seen the addition of technology players, including consumer-focused apps and online services, as well as digital health and digital therapeutics firms.</p>
<p class="photo-frame text-center"><img style="width: 100%;" src="/assets/rbccm/images/gib/healthcare/Healthcare-Article-3-Graph-1.png" alt="" /></p>
<h3>A Changing Ecosystem</h3>
<p>Indeed, digital and AI applications are radically changing key areas of the biopharma ecosystem and how patients manage their healthcare.</p>
<p>In pre-clinical research, technology is enabling everything from a deeper mining of literature, to predictive modeling and gene-function annotation. Digital apps are simulating molecular dynamics and pushing the limits of cellular imaging.</p>
<p>In clinical trials, digital transformation is helping to automate testing procedures, build global patient databases and collect real-world data.</p>
<p>In diagnostics, tech powers digital pathology, home-based body diagnosis, and computational analysis of tissue arrays. Just like your car leaves the factory with hundreds of sensors that can trigger the check engine light, humans will have wearable and/or implantable sensors to alert them when something is not functioning properly. Another burgeoning area is immune cell monitoring and digital analysis through just a finger prick.</p>
<p>At the point of patient care, digital applications are already delivering virtual consultations, remote monitoring, VR-based cognitive therapy and digital Rx. Demand for telehealth services and health-based social platforms is also increasing and especially vital in a world facing new challenges such as the COVID-19 pandemic.</p>
<p><img src="/assets/rbccm/images/gib/healthcare/healthcare-article-3-graph-2.png" alt="AI and Digital applications are changing key areas of the Healthcare Ecosystem" /></p>
<div id="similar-to-this" style="border-top: 2px #E6E6E7 dotted; border-bottom: 2px #E6E6E7 dotted; margin: 35px 0; padding: 25px;">
<h4 style="font-size: 18px; letter-spacing: 0.5px; border-bottom: 3px #FEDF01 solid; padding: 0 0 8px 0; margin-bottom: 15px;">Similar to this</h4>
</div>
<h3>Digital Transformation</h3>
<p>The digital revolution presents both threats and opportunities to incumbent biopharma companies. Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities from treatment to prevention.</p>
<div class="quotebox">
<p>“Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities.”</p>
<p class="attribution" style="color: #0070a3;">– Greg Wiederrecht, Ph.D.</p>
<div class="quote-share">
<p style="display: inline-block;"><span style="margin-right: 15px;">Share </span><a class="blue-circle-outline-sm" href="https://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New%20healthcare%20business%20models%20emerge&source=www.rbccm.com" target="_blank" rel="noopener" aria-label="Connect by LinkedIn"><em class="fa fa-linkedin" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="https://twitter.com/home?status=New%20business%20models%20emerge%20https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge" target="_blank" rel="noopener" aria-label="Connect by X"><em class="fa fa-twitter" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="mailto:?subject=New%20business%20models%20emerge&body=I%20found%20this%20insights%20piece%20from%20RBC%20Capital%20Markets%20informative%20and%20thought%20it%20might%20be%20of%20interest%20to%20you%3A%0D%0Dhttps%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New business models emerge" aria-label="Connect by Email"><em class="fa fa-envelope" style="color: #0051a5; margin-left: 3px;"> </em></a></p>
</div>
</div>
<p> </p>
<p>The increased digitization of human experiences gives access to a wealth of information and knowledge that could help intervene before disease has a chance to strike. A prime example of this is collating data from an Apple Watch to screen for irregular heart rhythms and detect undiagnosed atrial fibrillation. At the other end of the spectrum, digital transformation allows a completely new class of therapies such as digital therapeutics to support specific disorders.</p>
<p>McKinsey and Company’s international survey shows that more than 75% of patients expect to use digital healthcare services in the future.<sup>1</sup> Patients are seeking technology that delivers a level of care they can rely on and trust. Ultimately, the aim of the digital revolution is to develop healthier societies and lower the cost of care.</p>
<p style="word-wrap: break-word;"><sup>1 Source: McKinsey and Company, Healthcare’s Digital Future, July 2014. https://www.mckinsey.com/~/media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/Healthcares%20digital%20future/Healthcares%20digital%20future.ashx</sup></p><ul>
<li>Customer groups, R&D and competitors are all rapidly expanding</li>
<li>Tech is reinventing every facet of the biopharma ecosystem</li>
<li>Innovations in patient care is driving adoption of digital services</li>
</ul>text2 min1 minHealthcare Models, Digital Healthcare, Digital Healthcare Apps, Digital Health Diagnostics, Expanding R&D, Healthcare & Tech Convergence, Healthcare Services, Clinical Trials, Remote Patient Monitoring, Digital Therapeutics, Biopharma ecosystem, Cost of CareN/templatedata/rbccm/episode/data/healthcare/amazon_cvs_and_google_healthcare_reimagined/templatedata/rbccm/episode/data/healthcare/big_tech_vs_big_pharma/templatedata/rbccm/episode/data/healthcare/the_healthcare_data_explosionGreg Wiederrecht, Ph.D./assets/rbccm/images/gib/healthcare/greg-wiederrecht.jpgManaging Director, Healthcare Investment Bankinggreg.wiederrecht@rbccm.comhttps://www.linkedin.com/in/gregwiederrecht/Sasson Darwish/assets/rbccm/images/gib/healthcare/sasson-darwish.jpgManaging Director, AI, Analytics and IoT & Israel Country Coverage, Global Technology Investment Bankingsasson.darwish@rbccm.com https://www.linkedin.com/in/sassdarwish/Andrew Callaway/assets/rbccm/images/gib/healthcare/andrew-callaway.jpgManaging Director, Global Head of Healthcare Investment Bankingandrew.callaway@rbccm.comhttps://www.linkedin.com/in/andrew-cal-callaway
12025-04-01Special edition: Crunch time for the consumerIn this special edition, Lori leads a discussion on the state of the US consumer with three of RBC's senior US equity research analysts.noneInsights<li><a href="/en/">Home</a></li><li><a href="/en/insights.page">Insights </a></li><li><a href="/en/insights/markets-in-motion.page">Markets in Motion</a></li>/assets/rbccm/images/insights/2025/special-edition-crunch-time-for-the-consumer-th.jpghttps://player.captivate.fm/episode/41c67299-15ec-4607-9aaa-d480d157c641//assets/rbccm/images/insights/2025/special-edition-crunch-time-for-the-consumer-banner.jpghttps://www.rbccm.com/en/story/story.page?dcr=templatedata/article/story/data/2025/04/special-edition-crunch-time-for-the-consumermarkets<p><strong>The big things you need to know:</strong></p>
<ul>
<li>The team tackles some of the top questions in consumer-related conversations today, including what their company and industry level interactions and data have been telling them about the current state of the consumer, whether the consumer has been retreating or simply shifting their spend, what's happening in different consumer cohorts, what they think the biggest challenges are for the consumer at the moment, and how their companies are managing around tariffs.</li>
<li>Overall, the team comes to the conclusion that while many of the issues impacting the consumer aren't new, in the aggregate the current set of pressures feels different and conditions appear to have taken a turn for the worse. Nik notes that the tone at a recent industry event was the most downbeat of all of the year's he's been attending and highlights what he believes the incremental pressures are this year. Mike highlights how his proprietary pricing data was particularly weak in February and how weakness in housing has broadened regionally. Steve points out that many issues have been used to explain consumer weakness earlier this year (i.e. weather), but that the slowing that's been underway has persisted even with some of those things now in the rearview mirror.</li>
<li>On policy, all three noted that their companies have provided very little in the way of guidance related to tariffs, which will likely lead to a tricky reporting season. The team explores whether the companies in their industry will be able to pass along tariff costs via pricing, collectively concluding that it may vary by industry and will be very difficult to do in certain verticals.</li>
</ul>https://www.rbccm.com/en/insights/transcripts/special-edition-crunch-time.pageaudio1 min30 minMarkets in Motion, Consumer Industry, Tariffsenglobalinsights, markets-in-motion2/templatedata/rbccm/authors/data/lori-calvasinalori-calvasinaLori CalvasinaManaging Director & Global Head of Equity Strategy, RBC Capital MarketsN/assets/rbccm/images/authors/lori-calvasina.jpg<p>Lori Calvasina joined RBC Capital Markets as Head of U.S. Equity Strategy in 2017 as a Managing Director. Having spent nearly two decades as an equity strategist at major investment banks, Lori is an expert on the US stock market, and regularly represents RBC in the financial media on Bloomberg and CNBC. Prior to joining RBC, Lori was a senior equity strategist at Credit Suisse from 2010 to 2017, covering Small/Mid Cap Strategy from 2010-2014 and both Small/Mid Cap and US Equity Strategy from 2015-2017. She spent the first ten years of her career at Citi in a variety of roles including lead Small/Mid Cap Strategist from 2007-2010. In both 2008 and 2009 Lori was ranked #2 in the Small Companies category in the Institutional Investor All America Research team poll. Lori is a graduate of the University of Virginia and its selective Government & Foreign Affairs’ Honors Program. In 2019, she was named to Crains New York’s list of Notable Women in Finance.</p>/templatedata/rbccm/authors/data/nik-modinik-modiNik ModiConsumer Staples Equity Research Analyst, RBC Capital MarketsN/assets/rbccm/images/authors/nik-modi.png<p>Nik joined RBC Capital Markets in 2013 to provide coverage of tobacco, household products and beverages. He has more than 15 years of research experience, most recently at UBS, where he was a senior analyst specializing in tobacco and household personal care as well as the global coordinator for UBS' global consumer staples effort, which encompassed more than 200 companies across the world. Nik has been ranked No. 2 in Institutional Investors’ tobacco category for six consecutive years. He is a Managing Director of RBC Capital Markets.</p>/templatedata/rbccm/authors/data/mike-dahlmike-dahlMike DahlManaging Director, Equity Research - Homebuilders & Building Products Analyst, RBC Capital MarketsN/assets/rbccm/images/authors/mike-dahl.jpg<p>Mike Dahl joined RBC Capital Markets in May 2018 as a Managing Director and Senior Analyst in Equity Research responsible for coverage of the U.S. Homebuilders & Building Products sector, currently based in Boston. Mike has covered the sector for 18+ years, and was most recently awarded a Runner-Up ranking (#4) in the 2024 Institutional Investor All-America Research Poll. Mike was also Runner-Up (#5) in 2023, after being recognized as the #3 ranked analyst in his sector in 2020-2022, and Runner-Up (#4) in 2019. Prior to joining RBC, he led coverage of Homebuilders & Building Products at Barclays Capital as a Director in Equity Research, beginning in 2016. Before joining Barclays, Mike was a Director at Credit Suisse Securities, where he worked from 2008-2016, first as part of a top-ranked Homebuilders & Building Products research franchise before becoming the Senior Analyst in 2014. Mike began his career at Banc of America Securities in 2006, where he worked as an analyst on a top-ranked Homebuilders & Building Products research team. Mike graduated magna cum laude from Fordham University. </p>/templatedata/rbccm/authors/data/steven-shemeshsteven-shemeshSteven ShemeshU.S. Hardlines/Broadlines & Food Retail, Equity Analyst, RBC Capital MarketsN/assets/rbccm/images/authors/steven-shemesh.jpg<p>Steve Shemesh is the U.S. Hardlines/Broadlines & Food Retail Analyst at RBC Capital Markets. He joined the firm in 2015 and previously served as a member of the U.S. Consumer Staples team (specifically covering Household & Personal Care, Beverages, Packaged Food & Tobacco). Steve holds a BA in Economics from Rutgers University. </p>By <b>Lori Calvasina</b>, <b>Nik Modi</b>, <b>Mike Dahl</b> and <b>Steven Shemesh, RBC Capital Markets</b>By <b>Lori Calvasina</b>, <b>Nik Modi</b>, <b>Mike Dahl</b> and <b>Steven Shemesh, RBC Capital Markets</b>1/templatedata/article/story/data/2025/03/the-us-equity-market-exhales/templatedata/article/story/data/2025/03/walking-through-the-math-behind-our-updated-sp-500-forecasts/templatedata/article/story/data/2025/03/drawdowns-bear-case-stress-test-vibes-small-capsIn this special edition, Lori leads a discussion on the state of the US consumer with three of RBC's senior US equity research analysts. Listen now.rbc capital markets podcast, rbc insight, rbc markets in motion podcast, lori calvasina, us equity market, equity investor, equity podcast, consumer sector insights, consumer tariff impact, tariffs
Special edition: Crunch time for the consumer
In this special edition, Lori leads a discussion on the state of the US consumer with three of RBC's senior US equity research analysts.
Listen
and subscribe on:
Now playing:
By Lori Calvasina, Nik Modi, Mike Dahl and Steven Shemesh, RBC Capital Markets Published | 1 min
read
The big things you need to know:
The team tackles some of the top questions in consumer-related conversations today, including what their company and industry level interactions and data have been telling them about the current state of the consumer, whether the consumer has been retreating or simply shifting their spend, what's happening in different consumer cohorts, what they think the biggest challenges are for the consumer at the moment, and how their companies are managing around tariffs.
Overall, the team comes to the conclusion that while many of the issues impacting the consumer aren't new, in the aggregate the current set of pressures feels different and conditions appear to have taken a turn for the worse. Nik notes that the tone at a recent industry event was the most downbeat of all of the year's he's been attending and highlights what he believes the incremental pressures are this year. Mike highlights how his proprietary pricing data was particularly weak in February and how weakness in housing has broadened regionally. Steve points out that many issues have been used to explain consumer weakness earlier this year (i.e. weather), but that the slowing that's been underway has persisted even with some of those things now in the rearview mirror.
On policy, all three noted that their companies have provided very little in the way of guidance related to tariffs, which will likely lead to a tricky reporting season. The team explores whether the companies in their industry will be able to pass along tariff costs via pricing, collectively concluding that it may vary by industry and will be very difficult to do in certain verticals.
Managing Director & Global Head of Equity Strategy, RBC Capital Markets
Lori Calvasina joined RBC Capital Markets as Head of U.S. Equity Strategy in 2017 as a Managing Director. Having spent nearly two decades as an equity strategist at major investment banks, Lori is an expert on the US stock market, and regularly represents RBC in the financial media on Bloomberg and CNBC. Prior to joining RBC, Lori was a senior equity strategist at Credit Suisse from 2010 to 2017, covering Small/Mid Cap Strategy from 2010-2014 and both Small/Mid Cap and US Equity Strategy from 2015-2017. She spent the first ten years of her career at Citi in a variety of roles including lead Small/Mid Cap Strategist from 2007-2010. In both 2008 and 2009 Lori was ranked #2 in the Small Companies category in the Institutional Investor All America Research team poll. Lori is a graduate of the University of Virginia and its selective Government & Foreign Affairs’ Honors Program. In 2019, she was named to Crains New York’s list of Notable Women in Finance.
Nik Modi
Consumer Staples Equity Research Analyst, RBC Capital Markets
Nik joined RBC Capital Markets in 2013 to provide coverage of tobacco, household products and beverages. He has more than 15 years of research experience, most recently at UBS, where he was a senior analyst specializing in tobacco and household personal care as well as the global coordinator for UBS' global consumer staples effort, which encompassed more than 200 companies across the world. Nik has been ranked No. 2 in Institutional Investors’ tobacco category for six consecutive years. He is a Managing Director of RBC Capital Markets.
Mike Dahl
Managing Director, Equity Research - Homebuilders & Building Products Analyst, RBC Capital Markets
Mike Dahl joined RBC Capital Markets in May 2018 as a Managing Director and Senior Analyst in Equity Research responsible for coverage of the U.S. Homebuilders & Building Products sector, currently based in Boston. Mike has covered the sector for 18+ years, and was most recently awarded a Runner-Up ranking (#4) in the 2024 Institutional Investor All-America Research Poll. Mike was also Runner-Up (#5) in 2023, after being recognized as the #3 ranked analyst in his sector in 2020-2022, and Runner-Up (#4) in 2019. Prior to joining RBC, he led coverage of Homebuilders & Building Products at Barclays Capital as a Director in Equity Research, beginning in 2016. Before joining Barclays, Mike was a Director at Credit Suisse Securities, where he worked from 2008-2016, first as part of a top-ranked Homebuilders & Building Products research franchise before becoming the Senior Analyst in 2014. Mike began his career at Banc of America Securities in 2006, where he worked as an analyst on a top-ranked Homebuilders & Building Products research team. Mike graduated magna cum laude from Fordham University.
Steven Shemesh
U.S. Hardlines/Broadlines & Food Retail, Equity Analyst, RBC Capital Markets
Steve Shemesh is the U.S. Hardlines/Broadlines & Food Retail Analyst at RBC Capital Markets. He joined the firm in 2015 and previously served as a member of the U.S. Consumer Staples team (specifically covering Household & Personal Care, Beverages, Packaged Food & Tobacco). Steve holds a BA in Economics from Rutgers University.